Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of subcutaneous JKN2401 in chronic rhinosinusitis with nasal polyps
CTR20261957Phase 2Active
- Sponsor
- Joincare Pharmaceutical
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JKN2401 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Joincare Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
JKN2401
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20261957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261957.